AstraZeneca and Johnson & Johnson have restarted their late-stage trials after finding that serious illnesses in a few volunteers appeared not to be related to the vaccines.
The office was dedicated to the long-term safety of vaccines. Experts say plans to track coronavirus vaccines are fragmented and “behind the eight ball.”
In its destruction of American lives, treasure and well-being, this pandemic marks the greatest failure of U.S. governance since Vietnam.
Health officials say there is no link between the deaths and the flu vaccines. But the deaths, after two recent vaccine recalls, have raised safety fears among the public at a critical time.
The hotly contested strategy of deliberate exposure, known as a human challenge trial, could speed up the process of identifying effective coronavirus vaccines.
After months of caving to pressures from the White House, Commissioner Stephen Hahn and a band of agency scientists have eked out a few victories.
The threat posed by the virus makes randomized controlled trials extremely difficult. That means “real-life experiments” are especially important.
As winter approaches, we still need to be vigilant about taking precautions.
Friday’s announcement represents a shift in tone for the company and its leader, who has repeatedly emphasized the month of October in interviews and public appearances.
President Trump’s health secretary voiced optimism on Sunday that vaccines and treatments would soon save the day, but governors and experts issued bleak warnings about the public letting down its guard.
Some coronavirus vaccines rely on a shark-based product, but that doesn’t mean you shouldn’t get immunized.
A case in Nevada has spurred new concerns that people who have recovered from the infection may still be vulnerable. That’s unlikely, experts say.
The social network, which prohibits misinformation related to the coronavirus, has also banned other types of content in recent days.
For the founder of the Vaccine Confidence Project, squashing viral rumors means building trust — and avoiding the term “anti-vaxxer.”
Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts in Washington to curb drug prices.
As America retreats from world affairs, Russia is promising other nations help on the pandemic.
A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans.
Come spring, Americans may have their choice of several so-so coronavirus vaccines — with no way of knowing which one is best.
The months ahead will be difficult. But the medical cavalry is coming, and the rest of us know what we need to do.
Despite the crises of 2020, parents can realistically expect that children born today will outlive them. That wasn’t always the case.
Emergency-use authorizations, a formerly obscure corner of regulatory law, have become a centerpiece of the government’s response to the pandemic.
Several towns with large ultra-Orthodox Jewish populations are seeing coronavirus case rates that are among the highest in New York.
The “cell lines” used to develop monoclonal antibodies, as well as remdesivir and vaccines, began with fetal tissue decades ago.
The F.D.A. releases guidelines that had been trailed by politics: This is your morning tip sheet.
The coronavirus “is not going to be over by fall,” our health reporter Donald G. McNeil Jr. says. But on vaccines and other interventions, he finds reasons for optimism.
Mistrust of vaccines runs deep in African-American communities. Against formidable odds, Father Paul Abernathy and his teams are trying to convince residents of Pittsburgh’s historic Black neighborhoods to volunteer for trials testing a Covid-19 shot.
The guidelines make it highly unlikely that a coronavirus vaccine will be given emergency authorization by Election Day.
The F.D.A. proposed stricter guidelines for emergency approval of a coronavirus vaccine, but the White House chief of staff objected to provisions that would push approval past Election Day.
Dr. Moncef Slaoui, the head of Operation Warp Speed, talks to Kara Swisher about a data-driven timeline, sticking to the science and battle rhythms.
Speed and scale may matter more than absolute effectiveness when it comes to tests, masks, treatments and vaccines.
With fears of a “twindemic” in the United States this fall, here’s a guide to understanding what’s making you feel terrible.
Despite slim chances that its vaccine will be ready by October, Pfizer has big incentives to hint that it might be.
People with extra weight may struggle to mount a robust immune response to the coronavirus — and may respond poorly to a vaccine.
As health officials warn of a second major wave, growing numbers of people are dismissing the threat as media hype and sometimes embracing conspiracy theories.
Drug company workers, government officials and others have been injected. More will be soon, bewildering experts who worry about potential ill effects.
The Maryland company, which has never brought a vaccine to market, has started its Phase 3 trial in the United Kingdom, with plans to begin in the United States in October.
New York officials do not play a role in the approval of a vaccine, but could delay distribution if they believed the vaccine was not safe.
Unlike some of its competitors, Johnson & Johnson’s vaccine does not need to be frozen and may require just one shot instead of two.
The new guidelines underscore the fact that a vaccine is highly unlikely before the election.
We may not find out whether the vaccines prevent moderate or severe cases of Covid-19.
While scientists are rushing to develop an immunization for adults, no one has started the process yet for children.
Developing an effective vaccine is the first step. Then comes the question of how to deliver hundreds of millions of doses that may need to be kept at arctic temperatures.
Despite the president’s repeated claims that a vaccine will be available in October, scientists, companies and federal officials all say that most people won’t get one until well into next year.
The company hopes to earn the trust of the public and of scientists who have clamored for details of its study.
Side effects, you ask? So far, just a sense of having contributed to the salvation of humanity.
A public scolding of the C.D.C. chief was only the latest but perhaps the starkest instance when the president has rejected not just the policy advice of his public health officials but the facts and information that they provided.
Thrusting the issue of a coronavirus vaccine to the center of the campaign, Joe Biden said he trusted vaccines, but not a politicized development process. His comments came as the president publicly rebuked the top federal scientist.
Experts worry that the two diseases could overwhelm the health care system and create a new shortage of hospital beds and personal protective equipment.
Americans will need to take pandemic precautions well into 2021 — yes, even after a vaccine arrives.